Popular on Amzeal
- Sarah Novotny Joins Kosai as a Board Advisor: A New Chapter for Open Source Leadership - 136
- Summit Technologies Welcomes Angelo Mazzocco to Advisory Board - 130
- Morningscore Secures $700k in Funding to Build the Next Generation of AI SEO and Expand Globally
- OmegaBrand Introduces New Thermal Transfer Ribbons for Honeywell PC45t Printers
- Streetwise Artificial Intelligence Technology
- Stan Fitzgerald: A Profile in Resilience and Leadership with VFAF Veterans for America First Organizational Support for a Presidential Pardon
- Nola Blue Records signs legendary Maria Muldaur and estimable Candice Ivory
- Actuated Medical President & CEO Appointed as Chair of the Industrial Advisory Board for the Penn State Center for Biodevices
- Inframark Acquires Cornerstone Properties, Inc., Expanding Community Management Services in Arizona
- New Drug Application to the FDA for the Treatment of Suicidal Depression that Affects 13+ Million Americans Each Year: NRx Pharma: Stock Symbol:NRXP
Similar on Amzeal
- Alliance Homecare Appoints Amy Romero as CMO to Drive Growth of TrustHouse, Private In-Home Nursing and Concierge Care
- OneSolution® Dental Implant Centers Celebrates Over 15,000 Successful Full-Arch Cases
- The One Experience™, Inc. Announces Inspiring Lineup of Pathway Guides for The One 2025 Event
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- IntellaTriage Launches New Patient Engagement Service
- IntellaTriage Launches New Patient Engagement Service
- Dr. Lauren Anderson Led a Successful CE Event: Digital Planning and Execution
- Hawk Tuah VIP Shop launches Exclusive Merchandise line for Viral Meme Fans
- NuNorm Announces Stop Soldier Suicide as This Year's EQUAL Grant Recipient
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
Amzeal News/10571118
AVENTURA, Fla. - Amzeal -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on Amzeal News
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on Amzeal News
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on Amzeal News
- CredHub Partners with Property Management Inc. (PMI) to Offer Credit-Building Opportunities to PMI Franchisees Residents
- 85% of Organizations Fail Privacy Risk Assessments—Game-Changing Solutions Await
- Nature Morning AI Introduces ALLIE: The First Step Towards Open-Source AGI
- ShotTracker Announces Largest Staff Expansion In Company History
- ASI Releases 10th Annual Membership Performance Benchmark Report
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on Amzeal News
- Has the Key to Keeping Your Resolutions Been Here All Along?
- Alliance Homecare Appoints Amy Romero as CMO to Drive Growth of TrustHouse, Private In-Home Nursing and Concierge Care
- Windsor Brokers Launches 2% Interest on all Trading Accounts
- Meet Troy Hafeez: Innovator, Entrepreneur, Visionary
- AI pioneer & tech icon, Professor Chris Imafidon Lauds President Trump's $500 Billion AI Initiative
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on Amzeal News
- Safe Night Partners With Simsi To Offer A New Certification For Proactive Alliance With Rutgers University
- LookDeep Health Issues Open Call for Transparency in AI for Smart Hospitals
- AI Technology Advances in 2025, Fully Automated Solutions Reach the Investment World
- The One Experience™, Inc. Announces Inspiring Lineup of Pathway Guides for The One 2025 Event
- Top 10 Least Known Facts About AI That Everyone Should Know
- Dawson Church's Spiritual Intelligence Outlines 21st Century Progress Transforming Society
- Stange Law Firm Opens Divorce and Family Law Office in Louisville, Kentucky
- Stange Law Firm Expands to Houston, Bringing Family Law Services to Texas
- Outdoor Tech Lab Releases Comprehensive 2025 Satellite Phone Guide for Modern Adventurers
- A Look Back at Our 2024 Accomplishments: Complete Sliding Doors & Windows Continues to Lead with Excellence
- Franchising Success, One Pour at a Time
- FamBam Foods® Expands Healthy Snack Portfolio with Launch of Caulitos®
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks
- Ventura & Associates HTA Advisors Partners with Microsoft to Expand AI and Cloud Capabilities
- Advancements in Data Integration Propel Scientific Research on Biodiversity
- Veteran-Owned Artisan Teck Launches Comprehensive Software Development Services
- "Global Accreditation Failures: How the Wuhan Lab Certification Exposed Systemic Weaknesses and Paved the Way for COVID-19"
- Global Collaboration Enhances Accessibility of Climate Data for Scientific Research
- LokiBots Unveils New Digital Human Feature: Avatar!
- Get to know Dr. Raphael E. Cuomo, PhD, Professor and Scientist at the University of California, San Diego